| Home | May 2017News | Oxyrane raises USD49.5 Million in Series D financing |
| |
|
|
 Oxyrane raises USD49.5 Million in Series D financing- Oxyrane raises USD49.5 Million in Series D financing
- May 22, 2017
-
Global Private Group has invested in Biopharmaceutical Company dedicated to the development of enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than forty rare inherited diseases.
Series D financing round for the company raised USD 49.5M, Global Private Group was the sole arranger.
The current fund will enable Biopharmaceutical Company to advance its lead ERT treatment for Pompe disease from preclinical stages through to the end of phase I/II, as well as further preclinical development of other ERTs. Pompe disease (also called Glycogen storage disease type II or acid maltase deficiency) is a rare, serious disease in which acid alpha-glucosidase enzyme deficiency lead...
- View more at: http://www.1888pressrelease.com/oxyrane-raises-usd49-5-million-in-series-d-financing-pr-613966.html
|
Previous